Abstract | BACKGROUND: METHODS: Male C57BL/6J mice were implanted with an osmotic pump containing angiotensin II (Ang II). After 7 days of Ang II infusion, mice were also treated with either SAC/VAL, valsartan, enalapril or vehicle alone each day for 2 weeks. Blood pressure measurement was done weekly, and echocardiography was performed before and 3 weeks after infusion of Ang II. Histological analyses were done using extracted heart to investigate cardiac hypertrophy and fibrosis. RESULTS: Ang II markedly elevated blood pressures in all of the treatment groups, and there were no differences in the degree of blood pressure reduction among the SAC/VAL-, valsartan- and enalapril-treated groups. Echocardiography showed that SAC/VAL significantly suppressed the increase in left ventricular (LV) wall thickness and tended to decrease LV mass. In a histological analysis, SAC/VAL inhibited Ang II-induced cardiomyocyte hypertrophy, and individual cardiomyocytes in the SAC/VAL group were smaller than those in the valsartan and enalapril groups. Although previous studies using animal models of heart failure have indicated that SAC/VAL attenuates cardiac fibrosis, we found no supporting evidence in this setting. CONCLUSIONS:
|
Authors | Kohei Tashiro, Takashi Kuwano, Akihito Ideishi, Hidetaka Morita, Yoshiaki Idemoto, Masaki Goto, Yasunori Suematsu, Shin-Ichiro Miura |
Journal | Cardiology research
(Cardiol Res)
Vol. 11
Issue 6
Pg. 376-385
(Dec 2020)
ISSN: 1923-2829 [Print] Canada |
PMID | 33224383
(Publication Type: Journal Article)
|
Copyright | Copyright 2020, Tashiro et al. |